Experimental studies of agents with potential neuroprotective properties

Acta Ophthalmologica Scandinavica, Supplement

Volumn 77, Issue 229, 1999, Pages 27-28

  Wheeler, Larry A ^a  

^a ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AJMALINE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRIMONIDINE; GLUTAMIC ACID; MEMANTINE; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; PROTEIN BCL 2; RAUWOLSCINE; YOHIMBINE;

APOPTOSIS; CELL SURVIVAL; CONFERENCE PAPER; GENETIC REGULATION; GLAUCOMA; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; OPTIC NERVE; OPTIC NERVE ATROPHY; PRIORITY JOURNAL; RETINA GANGLION CELL; RETINA ISCHEMIA; SIGNAL TRANSDUCTION;

EID: 0033367545     PISSN: 13953931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Quigley HA, Nickells RW, Kerrigan LA et al. (1995): Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophth Vis Sci 36: 774-786.
2. Kerrigan LA, Zack DJ, Quigley HA, Smith SD & Pease ME (1997): TUNEL-positive ganglion cells in human open-angle Glaucoma. Arch Ophthamol 115: 1031-1035.
3. Nickells RW (1996): Retinal ganglion cell death in glaucoma: The how, the why and the maybe. J Glaucoma 5: 345-356.
4. Vorwerk CK, Lipton SA, Zurakowski D et al. (1996): Chronic low-dose glutamate is toxic to retinal ganglion cells. Invest Ophth Vis Sci 37(8): 1618-1624.
5. Dryer EB, Zurakowski D, Schumer RA, Podos SM & Lipton SA (1996): Elevated glutamate in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol 114: 299-305.
6. Duvdevani R, Rosner M, Belkin M, Sautter J, Sabel BA & Schwartz M (1990): Graded crush of the rat optic nerve as a brain injury model: combining electrophysiological and behavioral outcome. Restor Neurol Neurosci 2: 31-38.
7. Yoles E & Schwartz M (1998): Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch Ophthalmol 116: 906-910.
8. Garcia-Valenzuela E, Shareef S, Walsh J & Sharma SC (1995): Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res 61(1): 33-44.
9. Yoles E, Wheeler LA & Schwartz M (1999): Alpha-2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthal V15 Sci; in press.
10. Hicks D, Heidinger V, Mohand-Said S, Sahel J & Dreyfus H (1998): Growth factors and gangliosides as neuroprotective agents in excitotoxicity and ischemia. Gen Pharmacol 30(30): 265-273.
11. Sievers J, Hausmann B, Unsicker K & Berry M (1987): Fibroblast growth factors promote the survival or adult rat retinal cells after transection of the optic nerve. 76: 157-162.
12. Peinado-Ramon P, Salvador M, Villegas-Perez MP & Vidal-Sanz M (1996): Effects of axotomy and intraocular administration of NT-4, NT-3, and brain-derived neurotrophic factor on the survival of adult rat retinal ganglion cells. Invest Ophthalmol Vis Sci 37: 489-500.
13. Zhang C, Takahasi K, Lam TT & Tso MO (1994): Effects of basic fibroblast growth factor in retinal ischemia. Invest Ophthalmol Vis Sci 35(8): 3163-3168.
14. Wen R, Cheng T, Li Y, Cao W & Steinberg RH (1996): Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci 16(19): 5986-5992.
15. Peng M, Yiwen L, Zhijun L, Liu C, Latties A & Wen R (1998): Alpha-2-adrenergic agonists selectively activate extracellular signal-regulated kinases in Mueller cells in vivo. Invest Ophthal Vis Sci 39: 721-1726.
16. Hasson D, Lai RK, Chun T & Wheeler LA (1997): Functional protection of rat retina ischemic injury by brimonidine. Soc Neuroscience 23: 72-74.
17. Chao DT & Korsmeyer SJ (1998): Bc1-2 family: regulators of cell death. Ann Rev Immunol 16: 395-419.